Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|AMC-107||AMC||A Phase 2 Trial of Ixazomib for Kaposi Sarcoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|AMC-111||AMC||Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living with HIV: A Feasibility Study||Adult CIRB - Late Phase Emphasis||Available to Open|
|AMC-112||AMC||Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|AMC-108||AMC||Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|AMC-110||AMC||Risk-Adapted Therapy for HIV-Associated Anal Cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|PEPN2011||PEP-CTN||A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors||Pediatric CIRB||Available to Open|
|PEPN2111||PEP-CTN||A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# TBD) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma||Pediatric CIRB||Available to Open|
|PEPN1924||PEP-CTN||A Phase 2 Study of DS-8201A (NSC# 807708, IND# TBD) in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma||Pediatric CIRB||Available to Open|
|PEPN1812||PEP-CTN||A Phase 1 Trial of the CD123 X CD3 DART® Molecule Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia||Pediatric CIRB||Available to Open|
|PED-CITN-02||Pediatric CITN||GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Sarcoma and Neuroblastoma to Increase Systemic Tumor Exposure||Pediatric CIRB||Available to Open|